1. Home
  2. KEEL vs RAPP Comparison

KEEL vs RAPP Comparison

Compare KEEL & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Keel Infrastructure Corp. Common Stock

KEEL

Keel Infrastructure Corp. Common Stock

N/A

Current Price

$3.55

Market Cap

1.9B

Sector

Finance

ML Signal

N/A

Logo Rapport Therapeutics Inc.

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$43.27

Market Cap

2.3B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEEL
RAPP
Founded
N/A
2022
Country
Canada
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.3B
IPO Year
2020
2024

Fundamental Metrics

Financial Performance
Metric
KEEL
RAPP
Price
$3.55
$43.27
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$48.50
AVG Volume (30 Days)
36.9M
248.6K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
24.34
EPS
N/A
N/A
Revenue
$229,276,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
72.03
N/A
52 Week Low
$2.96
$22.75
52 Week High
$7.37
$52.93

Technical Indicators

Market Signals
Indicator
KEEL
RAPP
Relative Strength Index (RSI) 46.68 38.34
Support Level $3.10 $38.95
Resistance Level $3.85 $43.99
Average True Range (ATR) 0.25 2.12
MACD 0.09 -0.98
Stochastic Oscillator 52.20 6.32

Price Performance

Historical Comparison
KEEL
RAPP

About KEEL Keel Infrastructure Corp. Common Stock

Keel Infrastructure Corp is a North American digital infrastructure and energy company that develops and owns data centers and energy infrastructure for high-performance computing workloads, including AI. The group has a pipeline of 2.2 gigawatts and established grid interconnections already in place. It delivers scalable infrastructure solutions in high-demand power markets across Pennsylvania and Washington in the United States, and Quebec in Canada. It has data campuses in Moses Lake, Panther Creek, Sharon, Sherbrooke, and Scrubgrass.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: